Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
The NK and LAK activity of peripheral blood lymphocytes of leukemic patients as well as the susceptibility of their acute myeloid (AML) and lymphoblastic (ALL) leukemia cells to autologous and allogeneic LAKs were examined. In addition, neoplastic cells at diagnosis and at relapse were compared in the same patients for several features, including in vitro susceptibility to LAKs and to the drugs used in the induction phase, expression of MDR phenotype and of adhesion molecules, and differentiation markers. The NK activity of patients' LAK cells on K562 was significantly lower than that of a group of healthy donors whereas no differences were found in LAK activity as evaluated on Daudi cells. Three of 5 AML and 3 of 4 ALL were significantly more susceptible to autologous and allogeneic LAK lysis when blasts obtained at relapse were compared with leukemic cells of the same patients at diagnosis. This different lysability was not associated with in vitro modified sensitivity to drugs used in induction treatment. Moreover, no elevation in the expression of the multidrug-resistance (MDR)-related P170 glycoprotein was noted in relapsing leukemic cells. Even the expression of adhesion molecules and differentiation markers did not correlate with lysability of leukemic cells. These data demonstrate that relapsing leukemic blasts can be significantly lysed by LAK cells and suggest a rationale for adoptive immunotherapy with IL-2 and LAK cells in the treatment of acute leukemic patients.
Arienti
F
F
Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.
Gambacorti-Passerini
C
C
Borin
L
L
Rivoltini
L
L
Orazi
A
A
Pogliani
E M
EM
Corneo
G
G
Parmiani
G
G
D000328:Adult; D000943:Antigens, Differentiation / Q000502:physiology; D015815:Cell Adhesion Molecules / Q000502:physiology*; D004351:Drug Resistance; D006680:HLA Antigens / Q000502:physiology; D006801:Humans; D015979:Killer Cells, Lymphokine-Activated / Q000502:physiology*; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology / Q000473:pathology; D007948:Leukemia, Monocytic, Acute / Q000276:immunology / Q000473:pathology; D007951:Leukemia, Myeloid / Q000276:immunology / Q000473:pathology*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000473:pathology; D015479:Leukemia, Myelomonocytic, Acute / Q000276:immunology / Q000473:pathology; D015473:Leukemia, Promyelocytic, Acute / Q000276:immunology / Q000473:pathology; D010641:Phenotype; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000473:pathology*; D015375:Receptors, Interleukin-2 / Q000502:physiology; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured
D000943:Antigens, Differentiation; D015815:Cell Adhesion Molecules; D006680:HLA Antigens; D015375:Receptors, Interleukin-2